skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 next page
Refinado por: tipo de recurso: Anais de Congresso remover nível superior: Revistas revisadas por pares remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Nursing Clinical Documentation System Structured on NANDA-I, NOC, and NIC Classification Systems
Nursing Clinical Documentation System Structured on NANDA-I, NOC, and NIC Classification Systems
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Nursing Clinical Documentation System Structured on NANDA-I, NOC, and NIC Classification Systems

Peres, Heloisa Helena C ; de Almeida Lopes M da Cruz, Diná ; Tellez, Michelle ; de Cassia Gengo e Silva, Rita ; dos S Diogo, Regina Celia ; Ortiz, Diley Cardoso F ; Ortiz, Dóris R

Studies in health technology and informatics, 2015, Vol.216, p.943-943 [Periódico revisado por pares]

Netherlands

Texto completo disponível

Citações Citado por
2
Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation
Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation

Mariani, G. ; Cardoso, F. ; Besse-Hammer, T. ; Viganò, L. ; Liljegren, A. ; Verkh, L. ; Huang, X. ; Giorgetti, C. ; Bergh, J. ; Gianni, L.

JOURNAL OF CLINICAL ONCOLOGY, 2008, Vol.26 (15_suppl), p.14534-14534 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
BENEFIT ASSESSMENT OF NEW METASTATIC BREAST CANCER (MBC) TREATMENTS – A MULTI-STAKEHOLDER APPROACH
BENEFIT ASSESSMENT OF NEW METASTATIC BREAST CANCER (MBC) TREATMENTS – A MULTI-STAKEHOLDER APPROACH
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

BENEFIT ASSESSMENT OF NEW METASTATIC BREAST CANCER (MBC) TREATMENTS – A MULTI-STAKEHOLDER APPROACH

Gordon, Jenn ; Bernardini, Benato ; Biganzoli, Laura ; Cardoso, Fatima ; Espin, Jaime ; Miikkulainen, Kaisa ; Spence, Danielle ; Schuurman, Susanne ; Spitz, Sabine ; Wilking, Nils ; Zernik, Nicole ; Ujupan, Sonia

BREAST, 2019, Vol.48, p.S34 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study

Schmid, P ; Cortes, J ; Dent, RA ; Pusztai, L ; McArthur, HL ; Kummel, S ; Denkert, C ; Park, YH ; Hui, R ; Harbeck, N ; Takahashi, M ; Foukakis, T ; Reynier, MAM ; Ferreira, MIR ; Im, SA ; Cardoso, F ; Ding, Y ; Pan, W ; Tryfonidis, KE ; O'Shaughnessy, J

ANNALS OF ONCOLOGY, 2023, Vol.34, p.S1257 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study
Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study

Kummel, S ; Schmid, P ; Harbeck, N ; Takahashi, M ; Untch, M ; Boileau, JF ; Cortes, J ; McArthur, H ; Dent, R ; O'Shaughnessy, J ; Pusztai, L ; Foukakis, T ; Park, YH ; Hui, RN ; Cardoso, F ; Denkert, C ; Zhu, YL ; Pan, W ; Karantza, V ; Fasching, PA

ANNALS OF SURGICAL ONCOLOGY, 2023, Vol.30 (SUPPL 2), p.S295 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

Kummel, S ; Schmid, P ; Harbeck, N ; Takahashi, M ; Untch, M ; Boileau, JF ; Cortes, J ; McArthur, H ; Dent, R ; O'Shaughnessy, J ; Pusztai, L ; Foukakis, T ; Park, YH ; Hui, R ; Cardoso, F ; Denkert, C ; Zhu, Y ; Pan, W ; Karantza, V ; Fasching, P

BREAST, 2023, Vol.68, p.S63 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
Development of a patient-centered core outcome set for metastatic breast cancer
Development of a patient-centered core outcome set for metastatic breast cancer
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Development of a patient-centered core outcome set for metastatic breast cancer

de Ligt, KM ; de Rooij, BH ; Hedayati, E ; Karsten, MM ; Smaardijk, VR ; Velting, M ; Saunders, C ; Travado, L ; Cardoso, F ; Ramirez, EL ; Carney, NC ; Wengstrom, Y ; Ives, A ; Velikova, G ; Fialho, MDLS ; Koppert, L ; Van de Poll-Franse, LV

ANNALS OF ONCOLOGY, 2022, Vol.33, p.S213 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
Does baseline health-related quality of life scores (QLQC30) add prognostic value beyond clinical measures and improve prognostic accuracy in cancer RCTs?
Does baseline health-related quality of life scores (QLQC30) add prognostic value beyond clinical measures and improve prognostic accuracy in cancer RCTs?
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Does baseline health-related quality of life scores (QLQC30) add prognostic value beyond clinical measures and improve prognostic accuracy in cancer RCTs?

Machingura, A ; Musoro, J ; Taye, M ; Ringash, J ; Pe, M ; Coens, C ; Martinelli, F ; Tu, DS ; Basch, E ; Brandberg, Y ; Groenvold, M ; Eggermont, A ; Cardoso, F ; Van Meerbeeck, J ; van der Graaf, WTA ; Taphoorn, M ; Reijneveld, JC ; Soffietti, R ; Sloan, J ; Velikova, G ; Flechtner, H ; Bottomley, A

QUALITY OF LIFE RESEARCH, 2022, Vol.31, p.S83 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522

Pusztai, L ; Denkert, C ; O'Shaughnessy, J ; Cortes, J ; Dent, RA ; McArthur, HL ; Kuemmel, S ; Bergh, JCS ; Park, YH ; Hui, RN ; Harbeck, N ; Takahashi, M ; Untch, M ; Fasching, PA ; Cardoso, F ; Zhu, YL ; Pan, W ; Tryfonidis, K ; Schmid, P

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16) [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

Dent, RA ; Cortes, J ; Pusztai, L ; McArthur, HL ; Kuemmel, S ; Bergh, J ; Denkert, C ; Park, YH ; Hui, R ; Harbeck, N ; Takahashi, M ; Untch, M ; Fasching, PA ; Cardoso, F ; Haiderali, A ; Jia, L ; Nguyen, AM ; Pan, W ; O'Shaughnessy, J ; Schmid, P

ANNALS OF ONCOLOGY, 2022, Vol.33 (7), p.S600 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de2004  (6)
  2. 2004Até2008  (7)
  3. 2009Até2012  (6)
  4. 2013Até2020  (10)
  5. Após 2020  (12)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (39)
  2. Russo  (1)
  3. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.